Clinical Predictors of Outcome in MPN

Hematology/Oncology Clinics of North America

Volumn 26, Issue 5, 2012, Pages 1101-1116

  Passamonti, Francesco ^a   Maffioli, Margherita ^a   Merli, Michele ^a   Ferrario, Andrea ^a   Caramazza, Domenica ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

JAK2; Myelofibrosis; Polycythemia; Prognosis; Thrombocythemia

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 8; JANUS KINASE 2; TRANSCRIPTION FACTOR EZH2; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTERY THROMBOSIS; BLAST CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOVASCULAR RISK; CHROMOSOME TRANSLOCATION; CLONAL EVOLUTION; DISEASE COURSE; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; EXCISION REPAIR; FRAMESHIFT MUTATION; GENE MUTATION; GENOMIC INSTABILITY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INCIDENCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPING; LEUKOCYTE COUNT; LEUKOCYTOSIS; LOW RISK POPULATION; MALIGNANT TRANSFORMATION; META ANALYSIS (TOPIC); MISSENSE MUTATION; MYELOFIBROSIS; MYELOID METAPLASIA; NONSENSE MUTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; VEIN THROMBOSIS; VON WILLEBRAND DISEASE;

HUMANS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84866630727     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.07.009     Document Type: Review

References (97)

1. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
2. Passamonti F., Rumi E., Arcaini L., et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008, 93:1645-1651.
3. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953.
4. Passamonti F., Rumi E., Pungolino E., et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004, 117:755-761.
5. Passamonti F., Rumi E., Caramella M., et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008, 111:3383-3387.
6. Passamonti F., Rumi E., Arcaini L., et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 2005, 104:1032-1036.
7. Beer P.A., Delhommeau F., LeCouedic J.P., et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010, 115:2891-2900.
8. Passamonti F., Rumi E., Pietra D., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010, 24(9):1574-1579. [Epub 2010 Jul 15].
9. Gangat N., Wolanskyj A.P., McClure R.F., et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007, 21:270-276.
10. Gangat N., Strand J., Li C.Y., et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007, 138:354-358.
11. Barbui T., Thiele J., Passamonti F., et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011, 29:3179-3184.
12. Passamonti F., Rumi E., Arcaini L., et al. Blast phase of essential thrombocythemia: A single center study. Am J Hematol 2009, 84:641-644.
13. Bjorkholm M., Derolf A.R., Hultcrantz M., et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011, 29:2410-2415.
14. Barbui T., Barosi G., Birgegard G., et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011, 29:761-770.
15. Cervantes F., Passamonti F., Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008, 22:905-914.
16. Bilgrami S., Greenberg B.R. Polycythemia rubra vera. Semin Oncol 1995, 22:307-326.
17. Beer P.A., Erber W.N., Campbell P.J., et al. How I treat essential thrombocythemia. Blood 2011, 117:1472-1482.
18. Landolfi R., Marchioli R., Kutti J., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004, 350:114-124.
19. Passamonti F. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Clin Lymphoma Myeloma Leuk 2011, 11(Suppl 1):S25-S27.
20. Ziakas P.D. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008, 93:1412-1414.
21. Dahabreh I.J., Zoi K., Giannouli S., et al. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009, 33:67-73.
22. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840-846.
23. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
24. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008, 112:844-847.
25. Beer P.A., Campbell P.J., Scott L.M., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008, 112:141-149.
26. Tefferi A., Pardanani A., Lim K.H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23:905-911.
27. Gangat N., Tefferi A., Thanarajasingam G., et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol 2009, 83:17-21.
28. Reilly J.T. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia 2008, 22:1818-1827.
29. Carobbio A., Finazzi G., Antonioli E., et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008, 112:3135-3137.
30. Carobbio A., Antonioli E., Guglielmelli P., et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008, 26:2732-2736.
31. Passamonti F., Rumi E., Pascutto C., et al. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 2009, 7:1587-1589.
32. Palandri F., Polverelli N., Catani L., et al. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 2011, 90:933-938.
33. Caramazza D., Caracciolo C., Barone R., et al. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol 2009, 88:967-971.
34. Gangat N., Wolanskyj A.P., Schwager S.M., et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009, 115:5740-5745.
35. Berk P.D., Goldberg J.D., Donovan P.B., et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986, 23:132-143.
36. Wilkins B.S., Erber W.N., Bareford D., et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008, 111:60-70.
37. Thiele J., Kvasnicka H.M., Mullauer L., et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011, 117:5710-5718.
38. Passamonti F., Thiele J., Girodon F., et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012, 120(6):1197-1201.
39. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
40. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
41. Passamonti F., Elena C., Schnittger S., et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011, 117:2813-2816.
42. Lasho T.L., Pardanani A., Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010, 363:1189-1190.
43. Suessmuth Y., Elliott J., Percy M.J., et al. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol 2009, 147:450-458.
44. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42:722-726.
45. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
46. Olcaydu D., Rumi E., Harutyunyan A., et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica 2011, 96:367-374.
47. Kiladjian J.J., Chevret S., Dosquet C., et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011, 29:3907-3913.
48. Passamonti F., Malabarba L., Orlandi E., et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003, 88:13-18.
49. Passamonti F., Maffioli M., Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol 2012, 19:117-123.
50. Marchioli R., Finazzi G., Specchia G., et al. A large-scale trial testing the intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis 2011, 2011:794240.
51. Landolfi R., Di Gennaro L., Barbui T., et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109:2446-2452.
52. Vannucchi A.M., Antonioli E., Guglielmelli P., et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007, 21:1952-1959.
53. Hernandez-Boluda J.C., Pereira A., Cervantes F., et al. A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood 2012, 119(22):5221-5228. [Epub 2012 Apr 11].
54. Barbui T., Thiele J., Passamonti F., et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012, 119(10):2239-2241. [Epub 2012 Jan 13].
55. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113:2895-2901.
56. Passamonti F., Cervantes F., Vannucchi A.M., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
57. Gangat N., Caramazza D., Vaidya R., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29:392-397.
58. Tam C.S., Abruzzo L.V., Lin K.I., et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009, 113:4171-4178.
59. Barosi G., Berzuini C., Liberato L.N., et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988, 70:397-401.
60. Reilly J.T., Snowden J.A., Spearing R.L., et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997, 98:96-102.
61. Cervantes F., Pereira A., Esteve J., et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997, 97:635-640.
62. Tefferi A., Mesa R.A., Schroeder G., et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 113:763-771.
63. Passamonti F., Cervantes F., Vannucchi A.M., et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010, 116:2857-2858.
64. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
65. Rupoli S., Da Lio L., Sisti S., et al. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994, 68:205-212.
66. Tefferi A., Mesa R.A., Pardanani A., et al. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 2009, 84:265-267.
67. Tefferi A., Siragusa S., Hussein K., et al. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2010, 85:14-17.
68. Elena C., Passamonti F., Rumi E., et al. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2011, 96:167-170.
69. Morel P., Duhamel A., Hivert B., et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010, 115:4350-4355.
70. Patnaik M.M., Caramazza D., Gangat N., et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol 2010, 84:105-108.
71. Pereira A., Bruguera M., Cervantes F., et al. Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases. Eur J Haematol 1988, 40:355-361.
72. Chelloul N., Briere J., Laval-Jeantet M., et al. Prognosis of myeloid metaplasia with myelofibrosis. Biomedicine 1976, 24:272-280.
73. Mesa R.A., Hanson C.A., Rajkumar S.V., et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000, 96:3374-3380.
74. Barosi G., Viarengo G., Pecci A., et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001, 98:3249-3255.
75. Arora B., Sirhan S., Hoyer J.D., et al. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005, 128:42-48.
76. Alchalby H., Lioznov M., Fritzsche-Friedland U., et al. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT. Bone Marrow Transplant 2012, 47(1):143-145. [Epub 2011 Feb 28]. 10.1038/bmt.2011.17.
77. Rumi E., Passamonti F., Bernasconi P., et al. Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood 2010, 115:2719-2720.
78. Hussein K., Pardanani A.D., Van Dyke D.L., et al. International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010, 115:496-499.
79. Caramazza D., Begna K.H., Gangat N., et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011, 25:82-88.
80. Vaidya R., Caramazza D., Begna K.H., et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood 2011, 117(21):5612-5615. [Epub 2011 Mar 30].
81. Guglielmelli P., Barosi G., Specchia G., et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114:1477-1483.
82. Tefferi A., Lasho T.L., Huang J., et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008, 22:756-761.
83. Barosi G., Bergamaschi G., Marchetti M., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007, 110:4030-4036.
84. Guglielmelli P., Biamonte F., Score J., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011, 118:5227-5234.
85. Tefferi A., Vaidya R., Caramazza D., et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011, 29:1356-1363.
86. Campbell P.J., Griesshammer M., Dohner K., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006, 107:2098-2100.
87. Alchalby H., Badbaran A., Zabelina T., et al. Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010, 116(18):3572-3581. [Epub 2010 May 20].
88. Tefferi A., Lasho T.L., Patnaik M.M., et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 2010, 24:105-109.
89. Tefferi A., Meyer R.G., Wyatt W.A., et al. Comparison of peripheral blood interphase cytogenetics with bone marrow karyotype analysis in myelofibrosis with myeloid metaplasia. Br J Haematol 2001, 115:316-319.
90. Hussein K., Huang J., Lasho T., et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009, 82:255-259.
91. Hidaka T., Shide K., Shimoda H., et al. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol 2009, 83:328-333.
92. Gale R.P., Barosi G., Barbui T., et al. What are RBC-transfusion-dependence and -independence?. Leuk Res 2011, 35:8-11.
93. Verstovsek S., Mesa R.A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
94. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
95. Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
96. Pardanani A., Lasho T.L., Finke C.M., et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol 2012, 30:1087-1094.
97. Scott B.L., Gooley T.A., Sorror M.L., et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012, 119(11):2657-2664. [Epub 2012 Jan 10].